Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60-70% chance of cure with current R-CHOP chemoimmunotherapy. However, 30-40% of patients are refractory or relapsing. Many attempts failed to improve the outcome of DLBCL patients, including the intensification of R-CHOP regimen, consolidation, or maintenance therapy since the introduction of R-CHOP in 2000. Better understanding of both molecular biology of lymphoma cells and the tumor microenvironment raised the hope for future improvement of DLBCL patients' survival. Novel molecular findings have initiated clinical trials exploring targeted therapy based on driver genetic alterations with an intent to improve survival of high-risk subsets of patients. But the preliminary results remain ambiguous. The approach "agnostic" to specific molecular alterations of lymphoma cell includes antibody-drug conjugates (especially polatuzumab vedotin), immunotherapy comprising different antibodies with immunomodulatory effect (tafasitamab, lenalidomide), and T-cell engaging therapy (bispecific antibodies, early use of CAR T-cell). This approach could increase the cure rates and change the current therapeutic paradigm. However, better prognostic stratification, smarter designs of clinical trials, modification of endpoints including the use of ctDNA are needed. This review covers the complexity of DLBCL management.

1st Department of Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Zobrazit více v PubMed

Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975–2016. Bethesda, MD: National Cancer Institute; 2019. Available from: https://seer.cancer.gov/csr/1975_2016/. Accessed November 29, 2022.

Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276. doi:10.1182/blood-2005-06-2508 PubMed DOI PMC

Trneny M, Campr V, Janikova A, et al. The improving outcome of non-Hodgkin lymphoma (NHL) within 15 years period-real world data of national-wide lymphoma project. Haematologica. 2016;2016(101):479–480.

Cerhan JR, Kricker A, Paltiel O, et al. Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):15–25. doi:10.1093/jncimonographs/lgu010 PubMed DOI PMC

Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005;23(12):2797–2804. doi:10.1200/JCO.2005.07.155 PubMed DOI

Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–2045. doi:10.1182/blood-2010-03-276246 PubMed DOI PMC

Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511. doi:10.1038/35000501 PubMed DOI

Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848–2856. doi:10.1200/JCO.2014.60.2383 PubMed DOI PMC

Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545 PubMed DOI

Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200–207. doi:10.1200/JCO.2010.30.0368 PubMed DOI PMC

Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690. doi:10.1038/s41591-018-0016-8 PubMed DOI PMC

Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407. doi:10.1056/NEJMoa1801445 PubMed DOI PMC

Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551–568 e514. doi:10.1016/j.ccell.2020.03.015 PubMed DOI PMC

Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569 PubMed DOI PMC

Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg lymphoma biomarker consortium. J Clin Oncol. 2019;37(35):3359–3368. doi:10.1200/JCO.19.00743 PubMed DOI

Scott DW, King RL, Staiger AM, et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018;131(18):2060–2064. doi:10.1182/blood-2017-12-820605 PubMed DOI PMC

Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–2279. doi:10.1182/blood-2009-03-212191 PubMed DOI PMC

Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533–3537. doi:10.1182/blood-2009-05-220095 PubMed DOI

Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–3459. doi:10.1200/JCO.2011.41.0985 PubMed DOI PMC

Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2 PubMed DOI PMC

Cree IA. The WHO classification of haematolymphoid tumours. Leukemia. 2022;36(7):1701–1702. doi:10.1038/s41375-022-01625-x PubMed DOI PMC

Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229–1253. PubMed PMC

Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A. Report on the 4th international workshop on positron emission tomography in lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma. 2014;55(1):31–37. doi:10.3109/10428194.2013.802784 PubMed DOI

Mamot C, Klingbiel D, Hitz F, et al. Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015;33(23):2523–2529. doi:10.1200/JCO.2014.58.9846 PubMed DOI

Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118(1):37–43. doi:10.1182/blood-2010-12-327767 PubMed DOI

Schoder H, Polley MC, Knopp MV, et al. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020;135(25):2224–2234. doi:10.1182/blood.2019003277 PubMed DOI PMC

Duhrsen U, Muller S, Hertenstein B, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36(20):2024–2034. doi:10.1200/JCO.2017.76.8093 PubMed DOI

Zijlstra JM, Burggraaff CN, Kersten MJ, Barrington SF. FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice? Haematologica. 2016;101(11):1279–1283. doi:10.3324/haematol.2016.142752 PubMed DOI PMC

Vercellino L, Cottereau AS, Casasnovas O, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135(16):1396–1405. doi:10.1182/blood.2019003526 PubMed DOI PMC

Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL, Mahmood U. Baseline total lesion glycolysis measured with (18) F-FDGPET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging. 2013;3(3):272–281. PubMed PMC

Gallicchio R, Mansueto G, Simeon V, et al. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2014;92(5):382–389. doi:10.1111/ejh.12268 PubMed DOI

Adams HJ, de Klerk JM, Fijnheer R, et al. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Eur J Haematol. 2015;94(6):532–539. doi:10.1111/ejh.12467 PubMed DOI

Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452–1457. doi:10.1200/JCO.2010.33.3419 PubMed DOI

Chung R, Lai R, Wei P, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood. 2007;110(4):1278–1282. doi:10.1182/blood-2007-01-070300 PubMed DOI

Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800 PubMed DOI PMC

Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–3058. doi:10.1200/JCO.2013.53.5229 PubMed DOI PMC

International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994. doi:10.1056/NEJM199309303291402 PubMed DOI

Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861. doi:10.1182/blood-2006-08-038257 PubMed DOI

Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373–2380. doi:10.1200/JCO.2009.26.2493 PubMed DOI

Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842. doi:10.1182/blood-2013-09-524108 PubMed DOI PMC

Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041–2048. doi:10.1182/blood.2019002729 PubMed DOI

Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541–549. doi:10.1016/S1470-2045(15)70106-3 PubMed DOI PMC

Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36(28):2845–2853. doi:10.1200/JCO.2018.78.5246 PubMed DOI PMC

Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155. doi:10.1126/scitranslmed.aai8545 PubMed DOI PMC

Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413–2425. doi:10.1182/blood-2017-11-812073 PubMed DOI

McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38(4):1484–1493. doi:10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I PubMed DOI

Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002–1006. doi:10.1056/NEJM199304083281404 PubMed DOI

Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188–2195. doi:10.1182/blood.V90.6.2188 PubMed DOI

Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. doi:10.1056/NEJMoa011795 PubMed DOI

Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–3127. doi:10.1200/JCO.2005.05.1003 PubMed DOI

Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–1022. doi:10.1016/S1470-2045(11)70235-2 PubMed DOI

Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–116. doi:10.1016/S1470-2045(08)70002-0 PubMed DOI

Wasterlid T, Biccler JL, Brown PN, et al. Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic lymphoma group population-based study. Ann Oncol. 2018;29(8):1882–1883. doi:10.1093/annonc/mdy184 PubMed DOI

Sehn LH, Martelli M, Trneny M, et al. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020;13(1):71. doi:10.1186/s13045-020-00900-7 PubMed DOI PMC

Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339(1):21–26. doi:10.1056/NEJM199807023390104 PubMed DOI

Stephens DM, Li H, LeBlanc ML, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736. J Clin Oncol. 2016;34(25):2997–3004. doi:10.1200/JCO.2015.65.4582 PubMed DOI PMC

Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26(14):2258–2263. doi:10.1200/JCO.2007.13.6929 PubMed DOI

Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, Phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271–2281. doi:10.1016/S0140-6736(19)33008-9 PubMed DOI

Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174–181. doi:10.1182/blood-2017-07-793984 PubMed DOI PMC

Persky DO, Li H, Stephens DM, et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020;38(26):3003–3011. doi:10.1200/JCO.20.00999 PubMed DOI PMC

Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, Phase 2 trial. Lancet Oncol. 2011;12(5):460–468. doi:10.1016/S1470-2045(11)70069-9 PubMed DOI

Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 2004;22(21):4302–4311. doi:10.1200/JCO.2004.03.213 PubMed DOI

Tien YY, Link BK, Brooks JM, Wright K, Chrischilles E. Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile. Leuk Lymphoma. 2015;56(1):65–71. doi:10.3109/10428194.2014.903589 PubMed DOI PMC

Peyrade F, Bologna S, Delwail V, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017;4(1):e46–e55. doi:10.1016/S2352-3026(16)30171-5 PubMed DOI

Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165. doi:10.1200/JCO.19.00172 PubMed DOI PMC

Brem EA, Li H, Beaven AW, et al. SWOG 1918: a phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2022;13(2):258–264. doi:10.1016/j.jgo.2021.10.003 PubMed DOI PMC

Tanaka T, Sakai R, Choi I, et al. Comprehensive geriatric assessment as a useful tool in predicting adverse events in elderly patients with diffuse large B-cell lymphoma. Sci Rep. 2022;12(1):3124. doi:10.1038/s41598-022-07164-w PubMed DOI PMC

Merli F, Luminari S, Rossi G, et al. Outcome of elderly frail patients with Diffuse Large B-Cell Lymphoma (DLBCL) prospectively identified by Comprehensive Geriatric Assessment (CGA). Results from a study of the Intergruppo Italiano Linfomi (IIL). Blood. 2010;116(21):1771. doi:10.1182/blood.V116.21.1771.1771 DOI

Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634–641. doi:10.1182/blood-2003-06-2095 PubMed DOI

Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817–1826. doi:10.1016/S0140-6736(13)60313-X PubMed DOI

Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–1867. doi:10.1016/S0140-6736(11)61040-4 PubMed DOI

Le Gouill S, Ghesquieres H, Oberic L, et al. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. Blood. 2021;137(17):2307–2320. doi:10.1182/blood.2020008750 PubMed DOI

Gang AO, Strom C, Pedersen M, et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol. 2012;23(1):147–153. doi:10.1093/annonc/mdr058 PubMed DOI

Pedersen MO, Gang AO, Brown P, et al. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers. PLoS One. 2017;12(10):e0186983. doi:10.1371/journal.pone.0186983 PubMed DOI PMC

Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13(12):1250–1259. doi:10.1016/S1470-2045(12)70481-3 PubMed DOI

Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799. doi:10.1200/JCO.18.01994 PubMed DOI PMC

Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–e617. doi:10.1016/S2352-3026(18)30177-7 PubMed DOI PMC

Ohmachi K, Kinoshita T, Tobinai K, et al. A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Blood Adv. 2021;5(4):984–993. doi:10.1182/bloodadvances.2020002567 PubMed DOI PMC

Friedrichs B, Nickelsen M, Ziepert M, et al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Br J Haematol. 2019;184(5):760–768. doi:10.1111/bjh.15710 PubMed DOI

Lugtenburg PJ, de Nully Brown P, van der Holt B, et al. Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase III trial of the HOVON and the Nordic lymphoma group (HOVON-84). J Clin Oncol. 2020;38(29):3377–3387. doi:10.1200/JCO.19.03418 PubMed DOI

Freeman CL, Savage KJ, Villa DR, et al. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2021;137(7):929–938. doi:10.1182/blood.2020005846 PubMed DOI

Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545. doi:10.1056/NEJM199512073332305 PubMed DOI

Cortelazzo S, Tarella C, Gianni AM, et al. Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol. 2016;34(33):4015–4022. doi:10.1200/JCO.2016.67.2980 PubMed DOI

Epperla N, Hamadani M, Reljic T, et al. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: a systematic review and meta-analysis. Cancer. 2019;125(24):4417–4425. doi:10.1002/cncr.32464 PubMed DOI

Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: updated results of a phase Ib/II randomized study and preliminary results of a single-arm extension. Blood. 2020;136(Supplement 1):17–19. doi:10.1182/blood-2020-137078 DOI

Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021;5(13):2707–2716. doi:10.1182/bloodadvances.2020004155 PubMed DOI PMC

Vodicka P, Benesova K, Janikova A, et al. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. Eur J Haematol. 2022;109:162–165. doi:10.1111/ejh.13784 PubMed DOI

Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–363. doi:10.1056/NEJMoa2115304 PubMed DOI PMC

Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800. doi:10.1016/S1470-2045(21)00139-X PubMed DOI

Carlo-Stella C, Zinzani PLL, Janakiram M, et al. Planned interim analysis of a phase 2 study of loncastuximab tesirine plus ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3). Blood. 2021;138:54. doi:10.1182/blood-2021-147765 DOI

Wang ML, Barrientos JC, Furman RR, et al. Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evid. 2022;1(1):EVIDoa2100001. doi:10.1056/EVIDoa2100001 PubMed DOI

Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359–370. doi:10.1016/j.molcel.2019.09.030 PubMed DOI PMC

Frigault MJ, Armand P, Redd RA, et al. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020;4(1):122–126. doi:10.1182/bloodadvances.2019000784 PubMed DOI PMC

Smith SD, Till BG, Shadman MS, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020;189(6):1119–1126. doi:10.1111/bjh.16494 PubMed DOI

Hawkes EA, Chong G, Smith C, et al. Safety and efficacy of induction and maintenance avelumab plus R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL): analysis of the Phase II Avr-CHOP study. Blood. 2020;136(Supplement 1):43–44. doi:10.1182/blood-2020-136024 DOI

Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi:10.1056/NEJMoa1609783 PubMed DOI PMC

Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–1416. doi:10.1182/blood-2015-06-651380 PubMed DOI PMC

Katz DA, Chu MP, David KA, et al. Open-label, phase 2 study of blinatumomab after first-line rituximab-chemotherapy in adults with newly diagnosed, high-risk diffuse large B-cell lymphoma. Blood. 2019;134:4077. doi:10.1182/blood-2019-121708 PubMed DOI

Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959–1970. doi:10.1200/JCO.20.03175 PubMed DOI PMC

Olszewski AJ, Avigdor A, Babu S, et al. Mosunetuzumab monotherapy in elderly/unfit pts with first-line diffuse large B-cell lymphoma (DLBCL): safety and efficacy remain promising with durable complete responses. Hematol Oncol. 2021;39(S2). doi:10.1002/hon.152_2880 DOI

Phillips TJ, Olszewski AJ, Munoz J, et al. Mosunetuzumab, a novel CD20/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma. Blood. 2020;136:37–38. doi:10.1182/blood-2020-136295 DOI

Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980 PubMed DOI

Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi:10.1016/S0140-6736(20)31366-0 PubMed DOI

Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, Phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. doi:10.1016/S1470-2045(18)30864-7 PubMed DOI PMC

Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735–742. doi:10.1038/s41591-022-01731-4 PubMed DOI PMC

Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27(9):1902–1909. doi:10.1038/leu.2013.95 PubMed DOI

Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317–1328. doi:10.1200/JCO.20.01366 PubMed DOI PMC

Chamuleau MED, Burggraaff CN, Nijland M, et al. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. Haematologica. 2020;105(12):2805–2812. doi:10.3324/haematol.2019.238162 PubMed DOI PMC

Salles G, Duell J, Gonzalez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978–988. doi:10.1016/S1470-2045(20)30225-4 PubMed DOI

Belada D, Kopeckova K, Bergua JM, et al. First-MIND: a phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL. J Clin Oncol. 2021;39(15_suppl):7540. doi:10.1200/JCO.2021.39.15_suppl.7540 DOI

Vitolo U, Nowakowski GS, Burke JM, et al. ABCL-021: FRONT-MIND: a phase III, randomized, double-blind, placebo-controlled study comparing efficacy and safety of tafasitamab + lenalidomide + R-CHOP vs R-CHOP alone for newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL). Clin Lymphoma Myeloma Leuk. 2021;21:S376–S377.

Westin J, Davis RE, Feng L, et al. Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma. J Clin Oncol. 2022;Jco2200597. doi:10.1200/JCO.22.00597 PubMed DOI PMC

Buchner M, Muschen M. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol. 2014;21(4):341–349. doi:10.1097/MOH.0000000000000048 PubMed DOI PMC

Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295. doi:10.1200/JCO.18.02403 PubMed DOI PMC

Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(12):1643–1653.e1643. doi:10.1016/j.ccell.2021.10.006 PubMed DOI PMC

Sehn LH, Kahl BS, Matasar MJ, et al. ESCALADE: a phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2021;39(15_suppl):TPS7572–TPS7572. doi:10.1200/JCO.2021.39.15_suppl.TPS7572 DOI

Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):649–662. doi:10.1016/S1470-2045(18)30935-5 PubMed DOI PMC

Ravi D, Beheshti A, Abermil N, et al. Proteasomal inhibition by ixazomib induces CHK1 and MYC-dependent cell death in T-cell and Hodgkin lymphoma. Cancer Res. 2016;76(11):3319–3331. doi:10.1158/0008-5472.CAN-15-2477 PubMed DOI PMC

Galvez C, Karmali R, Hamadani M, et al. A phase I-II trial of DA-EPOCH-R plus ixazomib as frontline therapy for patients with MYC-aberrant lymphoid malignancies: the Daciphor regimen. Blood. 2020;136:44–45. doi:10.1182/blood-2020-138532 PubMed DOI PMC

Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600–609. doi:10.1182/blood.2020006578 PubMed DOI PMC

Abramson JS, Ruppert AS, Giri S, et al. Randomized phase II/III study of DA-EPOCH-R ± venetoclax in previously untreated double hit lymphoma: initial results from alliance A051701. Blood. 2021;138(Supplement 1):523. doi:10.1182/blood-2021-151266 DOI

Sarkozy C, Morschhauser F, Dubois S, et al. A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features. Clin Cancer Res. 2020;26(13):3145–3153. doi:10.1158/1078-0432.CCR-19-3741 PubMed DOI

Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511–e522. doi:10.1016/S2352-3026(20)30120-4 PubMed DOI

Thieblemont C, Tilly H, Gomes da Silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35(22):2473–2481. doi:10.1200/JCO.2017.72.6984 PubMed DOI

Witzig TE, Tobinai K, Rigacci L, et al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2018;29(3):707–714. doi:10.1093/annonc/mdx764 PubMed DOI

Crump M, Leppa S, Fayad L, et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2016;34(21):2484–2492. doi:10.1200/JCO.2015.65.7171 PubMed DOI

Eyre TA, Djebbari F, Kirkwood AA, Collins GP. Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica. 2020;105(7):1914–1924. doi:10.3324/haematol.2019.229948 PubMed DOI PMC

Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150–3156. doi:10.1200/JCO.2015.65.6520 PubMed DOI

Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019;133(9):919–926. doi:10.1182/blood-2018-07-862862 PubMed DOI PMC

Orellana-Noia VM, Reed DR, McCook AA, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022;139(3):413–423. doi:10.1182/blood.2021012888 PubMed DOI PMC

Bobillo S, Joffe E, Sermer D, et al. Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. Blood Cancer J. 2021;11(6):113. doi:10.1038/s41408-021-00506-3 PubMed DOI PMC

Jeong H, Cho H, Kim H, et al. Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis. Blood Adv. 2021;5(8):2142–2152. doi:10.1182/bloodadvances.2020003947 PubMed DOI PMC

Portell CA. CNS prophylaxis in DLBCL: first do no harm. Blood. 2022;139(16):2420–2421. doi:10.1182/blood.2022015432 PubMed DOI

Wilson MR, Eyre TA, Kirkwood AA, et al. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022;139(16):2499–2511. doi:10.1182/blood.2021014506 PubMed DOI

Mechanism of Action of circRNA/miRNA Network in DLBCL